Next Article in Journal
Relationship between Delta Rhythm, Seizure Occurrence and Allopregnanolone Hippocampal Levels in Epileptic Rats Exposed to the Rebound Effect
Next Article in Special Issue
Discovery and Optimization of Selective Inhibitors of Meprin α (Part II)
Previous Article in Journal
Methyl Jasmonate and Methyl-β-Cyclodextrin Individually Boost Triterpenoid Biosynthesis in Chlamydomonas Reinhardtii UVM4
Previous Article in Special Issue
(2-Aminobenzothiazole)-Methyl-1,1-Bisphosphonic Acids: Targeting Matrix Metalloproteinase 13 Inhibition to the Bone
Review

Targeting Cartilage Degradation in Osteoarthritis

Norwich Medical School, University of East Anglia, Bob Champion Research and Education Building, Rosalind Franklin Road, Norwich NR4 7UQ, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Salvatore Santamaria
Pharmaceuticals 2021, 14(2), 126; https://doi.org/10.3390/ph14020126
Received: 23 January 2021 / Revised: 30 January 2021 / Accepted: 1 February 2021 / Published: 5 February 2021
(This article belongs to the Special Issue Novel Approaches for Targeting Metalloproteinases)
Osteoarthritis is a common, degenerative joint disease with significant socio-economic impact worldwide. There are currently no disease-modifying drugs available to treat the disease, making this an important area of pharmaceutical research. In this review, we assessed approaches being explored to directly inhibit metalloproteinase-mediated cartilage degradation and to counteract cartilage damage by promoting growth factor-driven repair. Metalloproteinase-blocking antibodies are discussed, along with recent clinical trials on FGF18 and Wnt pathway inhibitors. We also considered dendrimer-based approaches being developed to deliver and retain such therapeutics in the joint environment. These may reduce systemic side effects while improving local half-life and concentration. Development of such targeted anabolic therapies would be of great benefit in the osteoarthritis field. View Full-Text
Keywords: osteoarthritis; cartilage; metalloproteinase; targeting osteoarthritis; cartilage; metalloproteinase; targeting
Show Figures

Graphical abstract

MDPI and ACS Style

McClurg, O.; Tinson, R.; Troeberg, L. Targeting Cartilage Degradation in Osteoarthritis. Pharmaceuticals 2021, 14, 126. https://doi.org/10.3390/ph14020126

AMA Style

McClurg O, Tinson R, Troeberg L. Targeting Cartilage Degradation in Osteoarthritis. Pharmaceuticals. 2021; 14(2):126. https://doi.org/10.3390/ph14020126

Chicago/Turabian Style

McClurg, Oliver, Ryan Tinson, and Linda Troeberg. 2021. "Targeting Cartilage Degradation in Osteoarthritis" Pharmaceuticals 14, no. 2: 126. https://doi.org/10.3390/ph14020126

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop